Morphine and tumor growth and metastasis

Afsharimani, Banafsheh; Cabot, Peter J.; Parat, Marie-Odile

doi:10.1007/s10555-011-9285-0

Cited by 157 publications

(122 citation statements)

References 97 publications

Supporting

Mentioning

116

Contrasting

Unclassified

Order By: Relevance

“…26 Nevertheless, it is possible that the putative improved outcome in cancer patients receiving local anesthetics and/or regional anesthesia is attributable to the concomitant pain relief leading to a reduced consumption of morphine, which has been reported to be proangiogenic. 45 Clearly, our studies need additional in vivo validation.…”

Section: Kip1mentioning

confidence: 98%

Antiproliferative Effects of Local Anesthetics on Mesenchymal Stem Cells

Lucchinetti

Awad²,

Rahman³

et al. 2012

Anesthesiology

139

View full text Add to dashboard Cite

Background: Mesenchymal stem cells (MSC) are self-renewing clonal progenitor cells of nonhematopoietic tissues that exhibit a marked tropism to wounds and tumors. The authors' studies aimed at exploring how local anesthetics would affect MSC biology. Methods: Proliferation, colony formation, in vitro wound healing, and bone differentiation assays of culture-expanded bone-marrow-derived murine MSC were performed in the presence of increasing concentrations of lidocaine, ropivacaine, and bupivacaine. Cytotoxicity was monitored by measuring lactate dehydrogenase activity and phosphatidylserine exposure/ propidium iodide staining (early apoptotic cells/necrotic cells). Measurements of mitochondrial function in intact and permeabilized cells, transcriptional changes, and changes in nuclear factor -light-chain-enhancer of activated B cells signaling in

show abstract

Section: Kip1mentioning

confidence: 98%

Antiproliferative Effects of Local Anesthetics on Mesenchymal Stem Cells

Lucchinetti

Awad²,

Rahman³

et al. 2012

Anesthesiology

139

View full text Add to dashboard Cite

show abstract

“…Naltrexone, being a specific antagonist of the opioid receptors, can influence the activity of intracellular signalling pathways found downstream of the G protein-coupled receptor. As the net actions of these pathways determine the fate of cells, naltrexone, as well as other opiates, is able to alter cellular function, and induce cell death (2)(3)(4)(5). Indeed, in addition to their universally accepted analgesic qualities, the opioids have also been widely reported to elicit a number of other cellular responses that lead to reductions in tumours.…”

Section: Introductionmentioning

confidence: 99%

Naltrexone at low doses upregulates a unique gene expression not seen with normal doses: Implications for its use in cancer therapy

Liu

Scott

Dennis

et al. 2016

International Journal of Oncology

View full text Add to dashboard Cite

Abstract. It has been reported that lower doses of the opioid antagonist naltrexone are able to reduce tumour growth by interfering with cell signalling as well as by modifying the immune system. We have evaluated the gene expression profile of a cancer cell line after treatment with low-dose naltrexone (LDN), and assessed the effect that adapting treatment schedules with LDN may have on enhancing efficacy. LDN had a selective impact on genes involved with cell cycle regulation and immune modulation. Similarly, the pro-apoptotic genes BAD and BIK1 were increased only after LDN. Continuous treatment with LDN had little effect on growth in different cell lines; however, altering the treatment schedule to include a phase of culture in the absence of drug following an initial round of LDN treatment, resulted in enhanced cell killing. Furthermore, cells pre-treated with LDN were more sensitive to the cytotoxic effects of a number of common chemotherapy agents. For example, priming HCT116 with LDN before treatment with oxaliplatin significantly increased cell killing to 49±7.0 vs. 14±2.4% in cultures where priming was not used. Interestingly, priming with NTX before oxaliplatin resulted in just 32±1.8% cell killing. Our data support further the idea that LDN possesses anticancer activity, which can be improved by modifying the treatment schedule.

show abstract

“…In contrast, opioids have been demonstrated in murine models to promote tumor cell apoptosis and reduce pain (which has been implicated in cancer recurrence) [33,38].…”

Section: Opioidsmentioning

confidence: 99%

Cancer Recurrence and Regional Anesthesia: The Theories, the Data, and the Future in Outcomes

Le-Wendling

Nin

Capdevila³

2016

Pain Med

View full text Add to dashboard Cite

Objective. More than one million people each year in the United States are diagnosed with cancer. Surgery is considered curative, but the perioperative phase represents a vulnerable period for residual disease to spread. Regional anesthesia has been proposed to reduce the incidence of recurrence by attenuating the sympathetic nervous system's response during surgery, reducing opioid requirements thus diminishing their immunosuppressant effects, and providing antitumor and antiinflammatory effects directly through systemic local anesthetic action. In this article, we present a description of the perioperative period, a summary of the proposed hypotheses and available literature on the effects of regional anesthesia on cancer recurrence, and put regional anesthesia in context in regard to its potential role in reducing cancer recurrence during the perioperative period.Methods. A literature review was conducted through PubMed by examining the following topics: effects of surgery on tumor progression, roles of multiple perioperative variables (analgesics, hypothermia, blood transfusion, beta-blockade) in cancer recurrence, and available in vitro, animal, and human studies regarding the effects of regional anesthesia on cancer recurrence.Results. in vitro, animal and human retrospective studies suppport the hypothesis that in certain types of cancer, regional anesthesia may be associated with lower recurrence rates. A few well-planned human randomized clinical trials are currently under way that may provide more solid evidence to substantiate or refute the benefits of regional anesthesia in reducing cancer recurrence.Conclusions. The benefits of regional anesthesia in reducing cancer recurrence have a sound theoretical basis and, in certain cancers, are supported by the existing body of literature. This article outlines the current state of our knowledge on the relationship between cancer progression and regional analgesia.

show abstract

Morphine and tumor growth and metastasis

Cited by 157 publications

References 97 publications

Antiproliferative Effects of Local Anesthetics on Mesenchymal Stem Cells

Antiproliferative Effects of Local Anesthetics on Mesenchymal Stem Cells

Naltrexone at low doses upregulates a unique gene expression not seen with normal doses: Implications for its use in cancer therapy

Cancer Recurrence and Regional Anesthesia: The Theories, the Data, and the Future in Outcomes

Contact Info

Product

Resources

About